Delaware
|
|
000-29169
|
|
98-0178636
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer Identification No.)
|
33
Harbour Square, Suite 202, Toronto, Ontario Canada
|
|
M5J
2G2
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure of
Directors or Certain Officers; Election of Directors; Appointment of
Certain
Officers; Compensatory Arrangement of Certain
Officers.
|
·
|
The
Board terminated Anna E. Gluskin as President and Chief Executive
Officer. Ms. Gluskin will remain a member of the
Board.
|
·
|
The
Board appointed Mark A. Fletcher as Interim President and Chief Executive
Officer effective immediately. Mr. Fletcher will continue as General
Counsel for the Company.
|
·
|
The
Board appointed John P. Barratt, an independent director who has served on
the Board since 2003, to serve as Chairman of the
Board.
|
·
|
The
Board removed Rose C. Perri as Secretary of the Company and appointed Mr.
Fletcher to this position. Ms. Perri will remain Chief
Operating Office and Chief Financial
Officer.
|
·
|
The
Board appointed a special committee comprised of its three independent
directors (Mr. Barratt, Brian T. McGee and Nola Masterson), the
responsibilities of which will include immediately commencing a search to
identify candidates to secure a permanent President and Chief Executive
Officer.
|
GENEREX BIOTECHNOLOGY CORPORATION. | |||
Date:
October 1, 2010
|
By:
|
/s/ Rose C. Perri | |
Rose C. Perri | |||
Chief Operating Officer |
|
By:
|
/s/ John P. Barratt | |
John P. Barratt | |||
Chairman | |||